as a first-in-a-class, oral p300/CBP inhibitor for the treatment of multiple myeloma, announced the initiation of DOMMINO-1, a pivotal Phase 2 clinical trial evaluating inobrodib 20 mg in combination with standard doses of pomalidomide (pom) and...
for the life sciences industry, delivering end-to-end support across the entire product lifecycle. With a presence in 150+ countries, operations in 50+ countries, and a team of over 2,000 professionals, PLG supports pharmaceutical, biotechnology,...
track record in securing access for, and launching, innovative medicines as well as driving commercial operations of up to €150m in revenue. Constance joins Avanzanite with more than two decades of experience across global biopharmaceutical...
for Parkinson's disease and other neurodegenerative disorders, announced it has emerged from stealth and has closed a new $21 million tranche of its Series A financing, bringing its total funding in equity and grants to $42 million. Investors...
also strongly condemned management’s compliance failures. Despite a Labor-Management Win-Win Agreement signed on December 1 to resolve a broad array of legal disputes—including aggravated trespassing, violations of the Public Interest Whistleblower...
drug development, and commercial leadership to Convergent, as the Company completes its Phase 2 study of CONV01-α, a prostate specific membrane antigen (PSMA)-targeted Actinium-225 (Ac-225) radioantibody in patients with metastatic...
work synergistically to prime and activate the immune system to eradicate myeloma cells that express the BCMA protein.1 This approval offers a potential new standard of care (SOC) as early as second line and brings a novel treatment approach for...
evidence supporting product safety, performance, and patient outcomes across global markets. Calaway brings more than 17 years of experience in clinical operations, evidence generation strategy, and regulatory-aligned research programs within the...
neuroprotective therapies in neurodegenerative diseases, today announced the final close of its oversubscribed $105 million Series C funding. The round was led by Morningside Ventures, IAG Capital Partners and Starbloom Capital, with participation...
between ages five weeks to five months and continues for approximately six months. It is estimated that approximately 5,000-10,000 infants are treated with HEMANGEOL annually in the United States. The transaction is expected to be accretive to 2026...
is contractual. US-Rx Care provides employers with a conflict-free model that eliminates pharmacy ownership, operates on a 100 percent pass-through basis for discounts and rebates, and charges a transparent administrative fee. This structure offers...
of the United States and Canada, and Eisai today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan). Merck’s first-in-class oral hypoxia-inducible factor-2...
3T Biosciences, an immunotherapy company changing the future of treatment for solid tumors and other immune-mediated diseases, announced the appointment of Rebeca Villarreal-Barragan, MBA, as head of clinical operations. In this role, Ms....
first participant has been dosed in Regimen I of the HEALEY ALS Platform Trial evaluating Neurizon's lead candidate, NUZ-001, for the treatment of amyotrophic lateral sclerosis (ALS). HEALEY ALS Platform Trial The HEALEY ALS Platform Trial...
from Ben Gurion University and an MBA from Tel Aviv University. He has served as CEO and owner of RonMed Ltd. since 2015 and brings decades of executive leadership experience in the healthcare and life sciences sectors. Over the past 5 years, Mr....
Antibody therapies are changing the treatment of cancer, inflammatory diseases and infections. However, many promising drug candidates fail in clinical trials. A study in Science Immunology shows that genOway's genO-hFcγR mouse model enables more...
review, applied artificial intelligence and bioinformatics solutions, and more. About ARUP Laboratories: Founded in 1984, ARUP Laboratories is a leading national reference laboratory and a nonprofit enterprise of the University of Utah Spencer Fox...
repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. In 2021, CollPlant entered into a development and global commercialization agreement for dermal and soft tissue fillers with...
Bruker Corporation announced new advancements to enable Functional Proteomics 2.0 workflows on the timsOmni™ mass spectrometer to enable disease researchers to move beyond canonical protein lists toward biologically or pathologically functional...
67Cu-SAR-bisPSMA (8 GBq each cycle). The participant is a 76-year-old man who was initially diagnosed with prostate cancer 15 years ago. He had radical prostatectomy to treat the primary disease and radiotherapy for local recurrence, having...